Aribiolab아리바이오랩

Aribiolab remains loss-making with tiny revenue, though its share price has risen sharply over the past year and filings show heavy convertible bond and rights offering activity.

Aribiolab, a Korean biotech developing vaccines and immunotherapies on its adjuvant platform, reported trailing revenue of about ₩173M and an operating loss of about ₩13.0B for the period to H1 2026. Its shares closed at ₩3,585 on 26 October 2026, up 36.3% over one year but well below the 52-week high of ₩6,720. The data does not include any product approval or commercial sales milestone.

What stands out

• Revenue has collapsed from ₩370.7B in 2024 to ₩158.6M in 2025, and trailing revenue to H1 2026 is about ₩173M, so the business is effectively pre-revenue at scale.
• Trailing net loss is about ₩14.9B with free cash flow of about -₩9.2B, against cash of about ₩6.9B, and borrowings are shown as not available in the data.
• Filings in September and October 2026 cover a rights offering, convertible bond issues, a bond acquisition decision and a change of largest shareholder, signalling significant financing and ownership activity.
• The internal fair value model gives about ₩566 per share, far below the current price, though this is a model output and not a forecast or rating.
• Foreign ownership is 0% and retail investors were net sellers over the last 20 days, while the stock is up 59.3% over three months.

What to watch

• Upcoming filings on the rights offering, convertible bond issuance and the sale of the company's own convertible bonds, including dilution effects on existing shareholders.
• Next periodic results, to see whether revenue and cash burn change from the current trailing figures.
• Progress on the hepatitis B therapeutic vaccine and other pipeline programmes; the data does not state any clinical or regulatory timelines.